Enantiopure titanocene complexes--direct evidence for paraptosis in cancer cells

Area of Science:

• Organometallic Chemistry
• Cancer Biology
• Cell Death Mechanisms

Background:

• Titanium compounds are explored for cancer therapy due to normal tissue tolerance.
• Current titanium anti-cancer agents face challenges with efficacy, selectivity, and understanding their mechanisms of action.

Purpose of the Study:

• To investigate the in vitro anti-tumor activity and cell death mode of enantiopure titanium compound TiCl2{η-C5H4CHEt(2-MeOPh)}2 (Cp(R)2TiCl2).
• To determine the active species and cellular pathways involved in Cp(R)2TiCl2-induced cell death.

Main Methods:

• In vitro clonogenic assays to assess anti-tumor activity of Cp(R)2TiCl2 stereoisomers.
• High-Performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), and Nuclear Magnetic Resonance (NMR) for hydrolysis studies.
• Cellular morphology and signaling pathway analysis (MAPK) to identify cell death mechanisms.

Main Results:

• Cp(R)2TiCl2 demonstrated selective in vitro anti-cancer activity, with (S,S)-Cp(R)2TiCl2 being twice as effective.
• Hydrolysis data indicated soluble [Cp(R)2Ti(OH)(OH2)](+) as the likely biological trigger.
• Cp(R)2TiCl2 induced paraptosis (Type III cell death) characterized by cytoplasmic vacuolization and ER swelling, independent of apoptosis.
• Unlike cisplatin, Cp(R)2TiCl2 did not affect cell cycle dynamics or induce DNA damage markers (γH2AX).

Conclusions:

• Enantiopure Cp(R)2TiCl2 exhibits selective anti-cancer properties.
• The compound triggers paraptosis, a distinct cell death pathway, differentiating it from cisplatin.
• Cp(R)2TiCl2 represents a novel class of anti-cancer agents with a unique mechanism of action.